Coenzyme Q10 benefits

Summary of the evidence

Does coenzyme Q10 help heart failure?

The 2021 Cochrane review pooled 11 trials (1,573 participants) comparing coenzyme Q10 with placebo or conventional treatment in people with heart failure. Most of the trials were small; dose, follow-up duration, and outcomes measured differed from trial to trial, and all had unclear or high risk of bias in one or more domains. ^[1]

The two moderate-certainty results were as follows: for all-cause death, RR 0.58 (95% CI 0.35–0.95), from only 1 trial (420 people); for hospitalization due to heart failure, RR 0.62 (0.49–0.78), from 2 trials (1,061 people). For heart attack (RR 1.62; 0.27–9.59) and stroke (RR 0.18; 0.02–1.48), results were uncertain. For left ventricular ejection fraction, the mean difference of 1.77 (0.09–3.44; 7 trials, 650 people) was of very low certainty; for exercise capacity and risk of adverse events, results were uncertain. The authors stated that there was no convincing evidence either to support or to refute it. ^[1]

The single trial providing the death result is Q-SYMBIO: in 420 people with moderate-to-severe heart failure, 100 mg of coenzyme Q10 three times daily or placebo was given for 2 years in addition to standard treatment. There was no significant change in the short-term endpoints (week 16); major cardiovascular events were seen in 15% versus 26% (HR 0.50; 95% CI 0.32–0.80). ^[2] According to the ISRCTN record, the trial’s sponsor is a Danish manufacturer of coenzyme Q10 supplements; the funders also include an international coenzyme Q10 association and a Japanese chemical company. ^[3] This information does not invalidate the result, but it calls for considering together that the death finding has not been confirmed by an independent second trial and that the result comes from a sponsored trial.

Does coenzyme Q10 help statin muscle symptoms?

Three meta-analyses reached different results by pooling different numbers of small RCTs.

Banach and colleagues found no dose–response relationship and stated that larger trials are needed. ^[4] Qu and colleagues said that coenzyme Q10 could be a complementary approach. ^[5] Kovacic and colleagues stated that the reduction found was in pain severity, that doses of 100–600 mg/day varied across trials, and that more research is needed for evidence-based recommendations; the meta-analysis was conducted with the financial support of the Applied Vitamin Research Association (GVF) in Germany, and the authors reported no conflict of interest. ^[6] All three analyses rest on small trials; read together, the effect appears “possible but uncertain.” Continuing statin treatment is the physician’s decision.

Does coenzyme Q10 prevent migraine?

The meta-analysis by Sazali and colleagues covered 6 trials (371 people) in adult migraine patients. No significant reduction was found in severity; reductions were found in attack duration (mean difference −0.19; 95% CI −0.27 to −0.11) and frequency (−1.52; −2.40 to −0.65); 2 of the 6 included trials reported receiving funding from drug manufacturers. ^[7] The AAN/AHS 2012 guideline had classified coenzyme Q10 as “possibly effective” (Level C); the AAN retired this guideline on September 16, 2015 because of safety concerns about butterbur and no longer considers its recommendations valid. ^[8] Therefore the current basis is not a guideline but a meta-analysis of small trials.

Does coenzyme Q10 lower blood pressure?

The 2022 meta-analysis by Zhao and colleagues pooled 26 trials (1,831 people) conducted in people with cardiometabolic disease. Coenzyme Q10 lowered systolic blood pressure compared with the control group (−4.77 mmHg; 95% CI −6.57 to −2.97); circulating coenzyme Q10 level rose by 1.62 µg/mL. The effect was more marked in those with diabetes and dyslipidemia and in trials longer than 12 weeks. According to GRADE, the evidence was of moderate certainty for systolic pressure and low certainty for diastolic pressure. ^[9] In the same analysis, the relationship between dose and systolic pressure was U-shaped rather than linear: the reduction was marked at doses of about 100–200 mg/day (nonlinearity P=0.004). The −4.77 mmHg is the mean across all doses; the analysis does not show that the reduction grows as the dose increases. ^[9] This result cannot be directly carried over to people without cardiometabolic disease. It is also not a finding that replaces blood pressure medications.

Does coenzyme Q10 increase male fertility?

The 2022 Cochrane review pooled 90 trials covering 10,303 subfertile men aged 18–65 attending a fertility clinic and 20 different oral antioxidants; the evidence was of very low to low certainty. When antioxidants were compared with placebo or no treatment, live birth rate might have been increased (OR 1.43; 95% CI 1.07–1.91; 12 RCTs, 1,283 men; very low certainty); when trials at high risk of bias were removed, the difference became nonsignificant (Peto OR 1.22; 0.85–1.75; 8 RCTs, 827 men). For clinical pregnancy rate, OR 1.89 (1.45–2.47; 20 RCTs, 1,706 men; low certainty) was found. Mild digestive complaints were more common in the antioxidant group (OR 2.70; 1.46–4.99). ^[10] This pooled result cannot be read as a finding specific to coenzyme Q10. In the single trial in the review comparing coenzyme Q10 with placebo and reporting live birth and clinical pregnancy (60 men), no evidence of an increase was found in either outcome (Peto OR 2.16; 95% CI 0.53–8.82). ^[10]

Does coenzyme Q10 work in Parkinson’s disease?

No benefit was shown. In the QE3 trial, 600 early Parkinson’s patients diagnosed within the past 5 years were randomized to placebo, 1,200 mg per day, or 2,400 mg per day of coenzyme Q10 (all received 1,200 IU per day of vitamin E); the trial was stopped because of the prespecified futility criterion. The mean worsening in the UPDRS score was 6.9 points in the placebo group, 7.5 in the 1,200 mg group, and 8.0 in the 2,400 mg group; both active groups showed a slight unfavorable trend compared with placebo, but the differences were not significant (p = 0.49 and 0.21). ^[11]

What is known about energy and vitality in healthy adults?

In an RCT published in 2026, 150 healthy adults with a mean age of 52.1 received commercial ubiquinone, ubiquinol, geranylgeraniol (GG), ubiquinol + GG, or placebo for 8 weeks. Ubiquinone and ubiquinol raised plasma coenzyme Q10 levels compared with placebo; however, there was no difference from placebo on health and vitality questionnaires (p > 0.16). A supplement company covered all costs of the study; the first author is on the same company’s scientific advisory board (according to the article, the company had no role in design and analysis). ^[12]

This guide does not recommend a personal dose; the doses above are amounts used in the trials.